07:00 , Sep 29, 2016 |  BC Innovations  |  Targets & Mechanisms

Hitting for the cycle

Driven by the need for antimalarial drugs that hit all stages of the life cycle of the malaria parasite, a group at the Broad Institute of MIT and Harvard has constructed and screened a diverse...
08:00 , Jan 15, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: P. falciparum P-type cation-transporter ATPase 4 (PfATP4)

Infectious disease INDICATION: Malaria Mouse and in vitro studies have identified a new ATPase inhibitor that could help treat malaria infections. Whole genome sequencing of mutant strains of the P. falciparum parasite resistant to the...
07:00 , Oct 20, 2014 |  BC Week In Review  |  Company News

Eisai, St. Jude Children's Research Hospital, Medicines for Malaria Venture deal

Eisai partnered with St. Jude and Medicines for Malaria Venture to conduct preclinical and clinical testing of antimalarial compound SJ733. SJ733, a Plasmodium falciparum P-type cation-transporter ATPase 4 (PfATP4) inhibitor, was developed by a consortium...
07:00 , Aug 4, 2014 |  BC Week In Review  |  Clinical News

Cipargamin: Phase II data

An open-label, Thai Phase II trial in 21 adults with uncomplicated Plasmodium vivax or P. falciparum malaria, including patients with resistant infections, showed that once-daily 30 mg oral KAE609 for 3 days met the primary...